Navigation Links
New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At,Annual Digestive Disease Week Meeting

o approved for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (Greater Than or Equal To 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.

Important Safety Information

NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.

The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain. In patients aged 12 to 17 years, the most frequently reported adverse events with NEXIUM include headache, diarrhea, abdominal pain, and nausea.

Symptomatic response to therapy does not preclude the presence of gastric malignancy.

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated with long-term omeprazole, of which NEXIUM is an enantiomer.

As with all PPIs, patients treated comcomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Like other PPIs, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts, digoxin). Concomitant administration of esomeprazole may reduce the plasma levels of atazanavir.

Concomitant administration of esomeprazole may reduce the plasma of atazanavir.

NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. For full Prescribing Information for NEXIUM please visit http://www.Nexium-us.com .

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:5/22/2015)... 22, 2015 Research and Markets ... the "Latest Regulations on Pharmaceutical International Multi-Center ... offering. This is first time in ... on international multi-center clinical trials of drugs in ... to be implemented on March 1, 2015. The ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x377m/north_american ) has announced the addition of ... by Type (Ankle Replacement, Digit Replacement, Elbow ... - Forecast to 2019" report to ... market for knee replacement was valued at ...
Breaking Medicine Technology:2015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... Inc. (Nasdaq: NLTX ), a biopharmaceutical company that ... schedule of its upcoming cenderitide presentation taking place at the ... Location: Ernest N. Morial Convention Center, Hall ... AM -11:15 AM (CDT) Poster Presentation: Board #256 ...
... N.J., March 29, 2011 Konica Minolta Sensing Americas, ... of color, light and shape, announces the launch of ... to the pharmaceutical industry at the 2011 Interphex show ... Convention Center. (Photo: http://photos.prnewswire.com/prnh/20100714/NY35146 ) ...
Cached Medicine Technology:Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 2Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 3
(Date:5/23/2015)... CA (PRWEB) May 23, 2015 With ... small businesses, are finding it increasingly difficult to provide ... which fail to provide adequate insurance for employees stand ... businesses been such an integral part of a business’s ... affordable healthcare for businesses, Online USA Doctors has created ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at ... the 2015 Congress of Future Medical Leaders in Boston, ... of “America’s highest achieving high school students.” , “I’m ... new goals and learn better study habits,” said Omar. ... which we can ask the surgeons questions.” , The ...
(Date:5/22/2015)... PITTSBURGH, Pa (PRWEB) May 22, 2015 ... Network (AHN) today announced a new partnership to ... program for the region. The initiative includes a new ... BodyStage live demonstration theater, and a new traveling ... in the fall of 2015. , Designed to ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Just 45 minutes more shut-eye a night might make a ... While the connection between a child,s weight and the amount ... new research has found a strong correlation between the two. ... a night had a 23 percent rate of obesity, while ...
... company says drug still has benefits , , MONDAY, Nov. ... Trasylol, a clotting drug using during heart surgery to prevent ... and Drug Administration to remove the drug from the American ... patient population in which the use of Trasylol (aprotinin) outweighs ...
... In a subset of patients suffering heart attack, ... treatment window ends isn,t justified, say researchers from Duke ... last year,s widely reported Occluded Artery Trial (OAT), which ... attacks if it were used more than 3 days ...
... HONG KONG, Nov. 5 Mass Financial Corp. ... a lawsuit in the Supreme Court of,British Columbia, ... for breach of contract and contract interference. In ... Michael Smith, President of MASS said the ...
... - Operating earnings up 9 percent to $490 million, - Diluted earnings ... ... ... Supply Chain ...
... 5 Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today reported ... months ended September 30, 2007, the,Company reported a net loss ... net loss of $8.1 million, or ($0.15) per share, for ... 30, 2007, the Company,reported a net loss of $28.1 million, ...
Cached Medicine News:Health News:Kids Who Skimp on Sleep Tend to Be Fatter 2Health News:Kids Who Skimp on Sleep Tend to Be Fatter 3Health News:Trasylol Pulled From Worldwide Market 2Health News:Trasylol Pulled From Worldwide Market 3Health News:Trasylol Pulled From Worldwide Market 4Health News:Delayed angioplasty -- big bucks, no bang 2Health News:Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages 2Health News:Cardinal Health Reports First Quarter Results 2Health News:Cardinal Health Reports First Quarter Results 3Health News:Cardinal Health Reports First Quarter Results 4Health News:Cardinal Health Reports First Quarter Results 5Health News:Cardinal Health Reports First Quarter Results 6Health News:Cardinal Health Reports First Quarter Results 7Health News:Cardinal Health Reports First Quarter Results 8Health News:Cardinal Health Reports First Quarter Results 9Health News:Cardinal Health Reports First Quarter Results 10Health News:Cardinal Health Reports First Quarter Results 11Health News:Cardinal Health Reports First Quarter Results 12Health News:Cardinal Health Reports First Quarter Results 13Health News:Cardinal Health Reports First Quarter Results 14Health News:Cardinal Health Reports First Quarter Results 15Health News:Cardinal Health Reports First Quarter Results 16Health News:Cardinal Health Reports First Quarter Results 17Health News:Cardinal Health Reports First Quarter Results 18Health News:Cardinal Health Reports First Quarter Results 19Health News:Cardinal Health Reports First Quarter Results 20Health News:Cardinal Health Reports First Quarter Results 21Health News:Cardinal Health Reports First Quarter Results 22Health News:Cardinal Health Reports First Quarter Results 23Health News:Cardinal Health Reports First Quarter Results 24Health News:Cardinal Health Reports First Quarter Results 25Health News:Cardinal Health Reports First Quarter Results 26Health News:Cardinal Health Reports First Quarter Results 27Health News:Cardinal Health Reports First Quarter Results 28Health News:Cardinal Health Reports First Quarter Results 29
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: